Pittsburgh, Jan. 04, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that Dr. Susan Catalano, Cognition’s co-founder and chief science officer, will make two presentations at the upcoming Sachs Associates Neuroscience Innovation Forum on January 7, 2018 at the Marine’s Memorial Club in San Francisco.
Dr. Catalano will be participating on a panel titled “Advances in Alzheimer’s and other Cognitive Disorders” at 10:25am PT, which will review advances in the understanding of Alzheimer’s disease, as well as novel therapeutic, diagnostic and biomarker tools in development. Additionally, Dr. Catalano will make a corporate presentation during which she will provide an update on Cognition’s disease-modifying drug candidate, CT1812. Dr. Catalano will review the CT1812 Phase 1b/2a clinical results that were announced at two late-breaking presentations at CTAD, and preview the clinical trials of CT1812 that are expected to commence during 2018. Dr. Catalano’s corporate presentation will take place at 3:20pm PT in The Heritage Room.
For more details on the Forum, visit www.sachsforum.com/nif-about.html.
Cognition’s lead product candidate, CT1812, has completed a Phase 1b/2a clinical study (COG0102) in patients with mild-to-moderate Alzheimer’s disease and has been granted Fast Track designation by the U.S. FDA. CT1812 is a highly brain penetrant molecule that acts as a selective sigma-2 receptor complex allosteric antagonist, displacing toxic beta amyloid (A) oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. This compound has been shown in multiple Alzheimer’s disease models to stop memory loss. Results from Study COG0102 were reported at a late-breaker oral presentation at the Clinical Trials on Alzheimer’s disease (CTAD) meeting in Boston in November 2017.
About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally available small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. CT1812 and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at http://www.cogrx.com.
This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.